Local control for identifying subgroups of interest in observational research: Persistence of treatment for major depressive disorder

International Journal of Methods in Psychiatric Research

Volumn 22, Issue 3, 2013, Pages 185-194

  Faries, Douglas E ^a   Chen, Yi ^a   Lipkovich, Ilya ^a   Zagar, Anthony ^a   Liu, Xianchen ^a,b   Obenchain, Robert L ^c  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Risk Benefit Statistics LLC   (United States)

Author keywords

Classification trees; Cluster analysis; Counterfactual; Patient heterogeneity

Indexed keywords

CYCLOHEXANOL DERIVATIVE; DELAYED RELEASE FORMULATION; DULOXETINE; THIOPHENE DERIVATIVE; VENLAFAXINE;

ADOLESCENT; ADULT; AGE; CAREGIVER; CLUSTER ANALYSIS; COMPARATIVE STUDY; DATA MINING; DECISION MAKING; DELAYED RELEASE FORMULATION; DEPRESSIVE DISORDER, MAJOR; DRUG COST; ECONOMICS; EDUCATION; FEMALE; HEALTH EDUCATION; HUMAN; INSURANCE; MALE; MIDDLE AGED; NONPARAMETRIC TEST; OBSERVATIONAL STUDY; PSYCHOLOGY; STATISTICS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; CAREGIVERS; CLUSTER ANALYSIS; CYCLOHEXANOLS; DATA MINING; DECISION MAKING; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DRUG COSTS; FEMALE; HEALTH EDUCATION; HUMANS; INSURANCE CLAIM REPORTING; MALE; MIDDLE AGED; OBSERVATIONAL STUDY AS TOPIC; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC; THIOPHENES; YOUNG ADULT;

EID: 84884694320     PISSN: 10498931     EISSN: 15570657     Source Type: Journal    
DOI: 10.1002/mpr.1390     Document Type: Article

References (34)

1. Benson K., Hartz, A.J. (2000) A comparison of observational studies and randomized, controlled trials. New England Journal of Medicine, 342(25), 1878-1886.
2. Berger M.L., Mamdani M, Atkins D., Johnson M.L. (2009) Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report - Part I. Value in Health, 12(8), 1044-1052.
3. Breiman L. (2001) Random forests. Machine Learning, 45(1), 5-32.
4. Breiman L., Friedman J., Stone C.J., Olshen R.A. (1984) Classification and Regression Trees, New York, Chapman & Hall/CRC.
5. Cantrell C.R., Eaddy M.T., Shah M.B., Regan T.S., Sokol M.C. (2006) Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Medical Care, 44(4), 300-303.
6. Cramer J.A., Roy A., Burrell A., Fairchild C.J., Fuldeore M.J., Ollendorf D.A., Wong P.K. (2008) Medication compliance and persistence: terminology and definitions. Value in Health, 11(1), 44-47.
7. Cox E., Martin B.C., Van Staa T., Garbe E., Siebert U., Johnson M.L. (2009) Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report - Part II. Value in Health, 12(8), 1053-1061.
8. Concato J., Shah N., Horwitz R.I. (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. New England Journal of Medicine, 342(25), 1887-1892.
9. Crystal S., Akincigil A., Bilder S., Walkup J.T. (2007) Studying prescription drug use and outcomes with medicaid claims data: strengths, limitations, and strategies. Medical Care, 45(10), S58-S65.
10. Cui Z., Faries D.E., Gelwicks S., Novick D., Liu X. (2012) Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third party payer perspective. Journal of Medical Economics, 15(1), 1-11.
11. D'Agostino R.B. Jr. (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statistics Medicine, 17(19), 2265-2281.
12. Davidoff F. (2009) Heterogeneity is not always noise: lessons from improvement. Journal of the American Medical Association, 302(23), 2580-2586.
13. Des Jarlais D.C., Lyles C., Crepaz N., the TREND Group. (2004) Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. American Journal of Public Health, 94(3), 361-366.
14. Foster J.C., Taylor J.M.C., Ruberg S.J. (2011) Subgroup identification from randomized clinical trial data. Statistics in Medicine, 30, 2867-2880.
15. Hernan M.A. (2004) A definition of causal effect for epidemiological research. Journal of Epidemiology & Community Health, 58(4), 265-271.
16. Johnson M.L., Crown W., Martin B.C., Dormuth C.R., Siebert U. (2009) Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report - Part III. Value in Health, 12(8), 1062-1073.
17. Kroenke K., Krebs E.E., Bair M.J. (2009) Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. General Hospital Psychiatry, 31(3), 206-219.
18. Lipkovich I., Dmitrienko A., Denne J., Enas G. (2011) Subgroup Identification based on Differential Effect Search (SIDES) - a recursive partitioning method for establishing response to treatment in patient subpopulations. Statistics Medicine, 30(21), 2601-2621.
19. Liu X., Chen Y., Faries D. (2011) Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder. ClinicoEconomics, 3, 63-72.
20. Mallinckrodt C.H., Watkin J.G., Liu C., Wohlreich M.H., Raskin J. (2005) Duloxetine in the treatment of major depressive disorder: a comparison of efficacy in patients with and without melancholic features. BMC Psychiatry, 5, 1.
21. Motheral B., Brooks J., Clark M.A., Crown W.H., Davey P., Hutchins D., Martin B.C., Stang P. (2003) A checklist for retrospective database studies - report of the ISPOR Task Force on Retrospective Databases. Value in Health, 6(2), 90-97.
22. Negassa A., Ciampi A., Abrahamowicz M., Shapiro S., Boivin J.F. (2005) Tree-structured subgroup analysis for censored survival data: validation of computationally inexpensive model selection criteria. Statistics and Computing, 15(3), 231-239.
23. Obenchain R.L. (2010) The local control approach using JMP. In Faries D., Leon A.C., Haro J.M., Obenchain R.L. (eds) Analysis of Observational Health Care Data Using SAS, pp. 151-192, Cary, NC: SAS Press.
24. Obenchain R.L. (2011) SAS Macros for "Local Control" Phases One and Two. Copyright (c) 2009, Foundation for the National Institutes of Health; Apache 2.0 License. (OMOP Version 1.4). http://members.iquest.net/~softrx [23 August 2011].
25. Perahia D.G., Pritchett Y.L., Kajdasz D.K., Bauer M., Jain R., Russell J.M., Walker D.J., Spencer K.A., Froud D.M., Raskin J., Thase M.E. (2008) A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Journal of Psychiatric Research, 42, 22-34.
26. Rosenbaum P.R. (2010) Design of Observational Studies. New York, Springer Science + Business Media, LLC.
27. Rosenbaum P.R., Rubin D.B. (1983) The central role of the propensity score in observational studies for causal effects. Biometrika, 70(1), 41-55.
28. Ruberg S., Chen L., Wang Y. (2010) The mean doesn't mean as much anymore: finding subgroups for tailored therapeutics. Clinical Trials, 7(5), 574-583.
29. Stafford R.S., MacDonald E.A., Finkelstein S.N. (2001) National patterns of medication treatment for depression, 1987 to 2001. Primary Care Companion Journal of Clinical Psychiatry, 3(6), 232-235.
30. Su X., Tsai C.L., Wang H., Nickerson D.M., Li B. (2009) Subgroup analysis via recursive partitioning. Journal of Machine Learning Research, 10, 141-158.
31. Vandenbroucke J.P. (2008) Observational research, randomised trials, and two views of medical science. PLoS Medicine, 5(3), e67.
32. Vandenbroucke J.P., von Elm E, Altman D.G., Gotzsche P.C., Mulrow C.D., Pocock S.J., Poole C, Schlesselman J.J., Egger M, for the STROBE Initiative. (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Medicine, 4(10), e297.
33. Wohlreich M.M., Wiltse C.G., Desaiah D, Ye W, Robinson R.L., Kroenke K, Kornstein S.G., Griest J.H. (2007) Duloxetine in practice-based clinical settings: assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study. Primary Care Companion Journal of Clinical Psychiatry, 9(4), 271-279.
34. Ye W, Zhao Y, Robinson R.L., Swindle R.W. (2011) treatment patterns associated with duloxetine and venlafaxine use for major depressive disorder BMC Psychiatry, 11, 19.